Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
A recent clinical trial found that the combination did not work.
Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.
The combination improved both overall survival and patient-reported outcomes.
Combining a custom cancer vaccine and a checkpoint inhibitor generated tumor-specific immune responses in a majority of patients.
Initial treatment with atezolizumab led to longer overall survival in people with high biomarker levels.
“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.
Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.
Tecentriq plus Abraxane was approved under accelerated approval based on progression-free survival.
Tecentriq combo slows progression of hard-to-treat breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.